Boston Scientific Corporation (BSX)

In the past six months, Boston Scientific's stock has been impacted by several key events. The company announced its fourth-quarter and full-year 2025 results, which included disappointing U.S. Electrophysiology (EP) sales and fiscal 2026 guidance that fell below expectations, leading to a stock price drop. Boston Scientific announced an agreement to acquire Penumbra, Inc. The company received FDA 510(k) clearance for its Asurys™ Fluid Management System. The CHAMPION-AF trial for the WATCHMAN FLX™ Left Atrial Appendage Closure Device met all primary and secondary safety and efficacy endpoints for stroke risk reduction, and the HI-PEITHO trial demonstrated that Boston Scientific's EKOS™ Endovascular System was superior to standard care for treating acute pulmonary embolism. Boston Scientific completed the acquisition of Valencia Technologies. The stock experienced a decline of 33.85% from April 10, 2025, to April 9, 2026. A federal securities class action lawsuit was filed against Boston Scientific related to the February 4, 2026, earnings announcement.

Boston Scientific's consolidated net sales do not exhibit a significant degree of seasonality. However, customer purchases of medical devices have historically been lower in the first and third quarters of the year, influenced by factors including product launches, acquisitions, regulatory and reimbursement approvals, and patient, physician, and employee holiday schedules. The COVID-19 pandemic significantly impacted procedure volumes in the first half of 2020, though the company anticipated a recovery in the latter half of that year.

Boston Scientific is a global medical technology leader focused on transforming lives through innovative medical solutions. The company's core businesses are organized into two reportable segments: Cardiovascular and MedSurg. The Cardiovascular segment includes interventional cardiology therapies, cardiac rhythm management devices, and electrophysiology products. The MedSurg segment includes devices for endoscopy, urology and pelvic health, neuromodulation, and interventional oncology and embolization products.

Boston Scientific's global corporate headquarters are in Marlborough, Massachusetts, U.S. Regional headquarters are located in France (Europe), Singapore (Asia Pacific), and Florida (Latin America). It has major technology centers in Minnesota, California, Ireland, and Costa Rica, and operates 13 manufacturing facilities worldwide. The company has a market presence in approximately 125 countries, with foreign sales accounting for nearly half of its total sales. Boston Scientific has demonstrated strong operational growth across the United States, Europe, Middle East and Africa (EMEA), Asia Pacific (APAC), and Latin America and Canada (LACA), with a significant focus on expanding in Emerging Markets.

In the past year, Boston Scientific has maintained a reputation for innovation and a commitment to patient-centered solutions and global growth. The company is recognized for its strong intellectual property in medtech and has emphasized its dedication to diverse clinical trials and improving its ESG score. However, the company's reputation has faced challenges, notably with the filing of a securities fraud lawsuit following the February 4, 2026, earnings announcement, which alleged misleading statements regarding its EP business. Historically, Boston Scientific has also been involved in high-profile patent infringement cases resulting in substantial payouts.

Boston Scientific Corporation's ownership structure is primarily institutional, with institutional investors holding approximately 47.26% to 90.48% of the company's stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Fmr Llc, State Street Corp, Geode Capital Management, Llc, Primecap Management Co/ca/, Capital World Investors, JPMorgan Chase & Co, Bank Of America Corp /de/, and Norges Bank. Individual investors and insiders hold a smaller percentage of the company's shares, with insiders owning approximately 0.16% to 2.61% of total shares outstanding. Promerica LP is noted as a significant shareholder, owning 3.68% of the company's shares.